MapLight Therapeutics adds two directors to its board

MapLight Therapeutics, Inc. (Nasdaq: MPLT) appointed Martin Babler and Troy Cox to its board of directors following their election at the company's annual meeting of stockholders on June 23, 2026.

Babler and Cox succeed Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., who did not stand for re-election. Babler has been appointed to the Audit Committee, and Cox has been named Chair of the Nominating and Corporate Governance Committee.

Babler has served as President, Chief Executive Officer and Chairman of the Board of Alumis Inc. since September 2021. He previously held the roles of President and Chief Executive Officer at Principia Biopharma Inc. from 2011 until its acquisition by Sanofi S.A. in 2020, and at Talima Therapeutics, Inc. Earlier in his career, he held leadership positions at Genentech, Inc., including Vice President of Immunology Sales and Marketing. He currently serves on the board of Prelude Therapeutics, Inc.

Cox previously served as President and Chief Executive Officer of Foundation Medicine, Inc. from 2017 to 2019, including through its acquisition by Roche in 2018. He also held a Senior Vice President role at Genentech, Inc. and executive positions at UCB BioPharmaceuticals, including President of CNS Operations, as well as roles at Sanofi-Aventis and Schering-Plough. Cox currently serves as Chair of the board of SOPHiA GENETICS SA and on the boards of Standard BioTools Inc. and Fuze Health.

Chris Kroeger, co-founder and Chief Executive Officer of MapLight, said the company is grateful to the departing directors for their service and noted that the two incoming members "bring substantial strategic, operational and governance experience."

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on central nervous system disorders.

You May Also Be Interested In

• Serve Robotics names Andreas Lieber to its board of directors
• TOYO Co. launches $50M direct offering for Texas solar facility
• ROC to acquire digital forensics firm ZTC for up to $3M